GRACE :: Lung Cancer

Immunotherapy Combinations: Best Balance of Activity and Tolerability?

ASCO 2015 Highlights 04

 

As more immunotherapeutics become available to treat lung cancer, research must determine how to balance efficacy, toxicities, and cost. That means finding which patients who will benefit from which drugs while maintaining good quality of life.

Download Transcript

Please feel free to offer comments and raise questions in our Discussion Forums.

 


Choices Among Immunotherapeutics May Be the Future of Lung Cancer Care

ASCO 2015 Highlights 03

 

Novel immunotherapy agent atezolizumab (MPDL3280A) looks superior to Taxotere (docetaxel) in a study, specifically for patients with PD-L1. What are the implications of multiple agents with similar mechanisms of action in the same clinical settings?

Download Transcript

Please feel free to offer comments and raise questions in our Discussion Forums.

 


Immunotherapy for Non-Squamous NSCLC: Should We be Using Biomarker Selection?

ASCO 2015 Highlights 02

 

The immune checkpoint inhibitor Opdivo (nivolumab) shows better efficacy than Taxotere (docetaxel) for advanced non-squamous NSCLC, but this was seen only in patients with PD-L1 protein expression on their tumor. Should we be using this as a biomarker?

Download Transcript

Please feel free to offer comments and raise questions in our Discussion Forums.

 


Immunotherapy for Squamous Non-Small Cell Lung Cancer

ASCO 2015 Highlights 01

 

Research released at the 2015 American Society of Clinical Oncology (ASCO) annual meeting showed great promise for squamous cell lung cancer patients taking the immunotherapy drug Opdivo (nivolumab). But can we predict which patients will do well on it?

Download Transcript

Please feel free to offer comments and raise questions in our Discussion Forums.

 


Serum Testing for Molecular Markers: Circulating Tumor Cells & Circulating Free DNA

GRACE Cancer Video Library - Lung

GCVL_LU-B10_Serum Testing for Molecular Markers: Circulating Tumor Cells & Circulating Free DNA

 

Dr. Jack West reviews new techniques for evaluating mutations from blood, including detection of circulating tumor cells (CTCs) or mutations in circulating free DNA (cfDNA) that can replace at least some tissue biopsies.

Download Transcript

Please feel free to offer comments and raise questions in our Discussion Forums.

 


Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Immunotherapy Patient Forum 2015 - Register Now

 

Immunotherapy Patient Forum 2014 Videos

Acquired Resistance Forum Videos

 

ALK+ Lung Cancer Patient Forum Videos

Join the GRACE Faculty

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog

Subscribe to the GRACEcast Podcast on iTunes

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243